Table 2.
Risks of various kidney outcomes between SGLT2i and GLP1RA users.
| Outcomes | SGLT2i (N = 2551) |
GLP1RA (N = 2551) |
SGLT2i vs GLP1RA |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative incidence |
Crude incidence rate (Events / 10,000 person-years) |
Cumulative incidence |
Crude incidence rate (Events / 10,000 person-years) |
||||||||||
| New events | Rate | Estimate | 95% CI | Follow-up person-years | New events | Rate | Estimate | 95% CI | Follow-up person-years | HR† | 95% CI | P-value | |
| Composite kidney outcome* | 153 | 6·00% | 384·5 | (326·0, 450·5) | 3979 | 187 | 7·33% | 518·1 | (446·5, 597·9) | 3610 | 0·771 | (0·620, 0·959) | 0·020 |
| Sustained reduction in eGFR ≥50% | 73 | 2·86% | 179·2 | (140·4, 225·3) | 4074 | 85 | 3·33% | 226·8 | (181·1, 280·4) | 3748 | 0·817 | (0·592, 1·127) | 0·219 |
| End-stage kidney disease | 27 | 1·06% | 65·6 | (43·2, 95·5) | 4115 | 46 | 1·80% | 120·2 | (88·0, 160·4) | 3826 | 0·532 | (0·328, 0·862) | 0·010 |
| Incident macroalbuminuria | 79 | 4·34% | 260·2 | (206·0, 324·3) | 3036 | 101 | 5·42% | 362·6 | (295·4, 440·6) | 2785 | 0·743 | (0·551, 1·003) | 0·052 |
Abbreviations: HR = Hazard ratio; CI = Confidence interval; eGFR = Estimated glomerular filtration rate.
⁎
Composite kidney outcome included sustained reduction in eGFR ≥50%, end-stage kidney disease (defined by eGFR <15mL/min/1·73m2, dialysis or kidney transplant), incident macroalbuminuria, or kidney-related mortality.
†
HR <1 indicates SGLT2i users had lower risks of kidney outcomes compared to GLP1RA users.
There was no death from kidney causes identified in this study during the follow-up period.